Tenaya Therapeutics, INC Form 4 insider transactions

Eric J Hyllengren, Chief Financial Officer of Tenaya Therapeutics, Inc., received 1,650,000 shares of common stock on July 13, 2026.

Director Williams R. Sanders was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Director Jeffrey T. Walsh was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Director Catherine Stehman-Breen was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Director Deepak Srivastava was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Director Karah Herdman Parschauer was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Director June Lee was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Director Amy L. Burroughs was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Tenaya Therapeutics CEO Faraz Ali sold 3,390 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Chief Medical Officer Whittemore Tingley sold 3,121 shares of Tenaya Therapeutics to cover tax obligations related to RSU vesting.

Tenaya Therapeutics SVP of Finance Tomohiro Higa sold 1,485 shares of common stock to satisfy tax withholding requirements related to RSU vesting.

A 10% owner and director of Tenaya Therapeutics, Column Group III GP, LP, and related entities, reported selling over 4.1 million shares of common stock in late February 2026.

Multiple entities and individuals associated with The Column Group, including directors, have reported the sale of over 800,000 shares of Tenaya Therapeutics common stock in late February 2026.

A 10% owner and director of Tenaya Therapeutics, The Column Group, reported significant sales of common stock totaling over 4.3 million shares across two days in February 2026.

Tenaya Therapeutics, Inc. granted 29,250 restricted stock units and options for 175,500 shares to SVP of Finance, Tomohiro Higa, as part of its 2021 Equity Incentive Plan.

Tenaya Therapeutics' Chief Medical Officer, Tingley Whittemore, received substantial restricted stock units and stock options under the company's 2021 Equity Incentive Plan.

Tenaya Therapeutics CEO Faraz Ali reported significant new equity awards, including restricted stock units and stock options, under the company's 2021 Equity Incentive Plan.

Tenaya Therapeutics' SVP of Finance, Tomohiro Higa, sold 1,367 shares of common stock at $1.33 per share to cover tax withholding obligations related to restricted stock unit vesting.

Tenaya Therapeutics' Chief Medical Officer, Tingley Whittemore, sold 2,877 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Tenaya Therapeutics CEO Faraz Ali sold 3,126 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Tenaya Therapeutics' SVP of Finance, Tomohiro Higa, sold common stock to cover tax obligations related to restricted stock unit vesting.

Tenaya Therapeutics' Chief Medical Officer, Tingley Whittemore, sold 5,053 shares of common stock at a weighted average price of $1.253 to cover tax withholding obligations related to RSU vesting.

Tenaya Therapeutics CEO Faraz Ali sold common stock to cover tax withholding obligations related to restricted stock unit vesting.

Catherine Stehman-Breen, a Director at Tenaya Therapeutics, Inc., was granted 107,400 stock options with an exercise price of $0.4444 per share.

Jeffrey T. Walsh, a Director at Tenaya Therapeutics, Inc., was granted 107,400 stock options with an exercise price of $0.4444 per share, vesting over approximately one year.

Tenaya Therapeutics, Inc. Director Amy L. Burroughs was granted 107,400 stock options with an exercise price of $0.4444, vesting over the next year.

David V. Goeddel, a Director and 10% Owner of Tenaya Therapeutics, Inc., was granted 107,400 stock options with an exercise price of $0.4444, vesting over the next year.

A recent SEC Form 4 filing reveals that R. Sanders Williams, a Director at Tenaya Therapeutics, Inc., was granted 107,400 stock options with an exercise price of $0.4444.

Deepak Srivastava, a Director at Tenaya Therapeutics, Inc. (TNYA), was granted 107,400 stock options with an exercise price of $0.4444, vesting in May 2026.

Tenaya Therapeutics, Inc. Director June Lee was granted 107,400 stock options with an exercise price of $0.4444, vesting in May 2026 or earlier.